{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    10,
    13,
    18,
    24,
    39,
    46,
    47,
    52,
    53
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Exclusion Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.3.3",
        "sectionTitle": "Exclusion criteria",
        "description": "Reference to exclusion criteria section in inclusion criteria list"
      },
      {
        "id": "ref_2",
        "name": "Exclusion 29 Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.3.3",
        "sectionTitle": "Exclusion criteria",
        "description": "Specific reference to exclusion #29 regarding medical devices"
      },
      {
        "id": "ref_3",
        "name": "Drug Profile Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1.2",
        "sectionTitle": "DRUG PROFILE",
        "description": "Reference to drug profile for tolerability and safety info"
      },
      {
        "id": "ref_4",
        "name": "Administrative Structure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Administrative structure of the trial",
        "description": "Reference for details on DMC and adjudication committees"
      },
      {
        "id": "ref_5",
        "name": "Statistical Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7.4",
        "sectionTitle": "Statistical Methods",
        "description": "Reference for interim analysis details"
      },
      {
        "id": "ref_6",
        "name": "Stratification Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.3",
        "sectionTitle": "SELECTION OF TRIAL POPULATION",
        "description": "Reference for information on stratification and capping"
      },
      {
        "id": "ref_7",
        "name": "Packaging Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1.6",
        "sectionTitle": "Packaging, labelling and re-supply",
        "description": "Reference for drug packaging details"
      },
      {
        "id": "ref_8",
        "name": "Illiterate Procedure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.1",
        "sectionTitle": "Appendix 10.1",
        "description": "Reference for procedures for illiterate patients"
      },
      {
        "id": "ref_9",
        "name": "NYHA Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.3",
        "sectionTitle": "Appendix 10.3",
        "description": "Reference for NYHA functional classification severity"
      },
      {
        "id": "ref_10",
        "name": "MRS Appendix Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "10.4",
        "sectionTitle": "Appendix 10.4",
        "description": "Reference for Modified Rankin Scale for stroke outcome"
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "For Japan only: The following events will be handled as 'deemed serious for any other reason': AEs which possibly lead to disability will be reported as SAEs.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3.7.1",
        "pageNumber": 54
      },
      {
        "id": "annot_2",
        "text": "Cancers of new histology and exacerbations of existing cancer must be reported as a serious event regardless of the duration between discontinuation of the drug and the occurrence of the cancer.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "5.3.7.1",
        "pageNumber": 54
      },
      {
        "id": "annot_3",
        "text": "The investigator must document the reason why patient not on target dose per local guidelines.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Main criteria for inclusion",
        "pageNumber": 3
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "4.0",
        "status": "Final",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2019-11-20",
        "description": "Final Protocol (Revised Protocol (based on Global Amendment 03))",
        "amendmentNumber": "Global Amendment 03"
      }
    ],
    "summary": {
      "referenceCount": 10,
      "annotationCount": 3,
      "versionCount": 1
    }
  }
}